Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Treprostinil
Drug ID BADD_D02268
Description Treprostinil is a synthetic analogue of prostacyclin, used to treat pulmonary hypertension.
Indications and Usage For use as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.
Marketing Status approved; investigational
ATC Code B01AC21
DrugBank ID DB00374
KEGG ID D06213
MeSH ID C427248
PubChem ID 6918140
TTD Drug ID D01WUA
NDC Product Code 0703-0696; 0781-3430; 11014-0094; 66302-350; 66302-648; 66302-748; 66302-361; 66302-363; 66302-620; 66302-720; 0703-0676; 43598-646; 43598-647; 66302-302; 66302-325; 66302-616; 66302-362; 0703-0666; 14501-0015; 42023-209; 62332-515; 66302-110; 66302-300; 66302-610; 54893-0024; 43598-649; 62332-514; 62332-517; 66302-102; 66302-206; 66302-732; 58159-041; 68245-0008; 43598-648; 66302-120; 66302-600; 66302-650; 66302-764; 0703-0686; 0781-3420; 0781-3425; 81861-0029; 66302-101; 66302-310; 66302-630; 66302-664; 0781-3427; 42023-206; 66302-105; 66302-640; 42023-207; 62332-516; 66302-632; 66302-716; 42023-208
UNII RUM6K67ESG
Synonyms treprostinil | ((1R,2R,3AS,9AS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3A,4,9,9A-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate | treprostinil sodium | trepostinil sodium | Orenitram | UT-15 | UT-15C | Remodulin | treprostinil diolamine | treprostinil diolamin | treprostinil diethanolamine
Chemical Information
Molecular Formula C23H34O5
CAS Registry Number 81846-19-7
SMILES CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cardiac dysfunction02.11.01.0040.000181%Not Available
Catheter site discharge12.07.02.016; 08.02.02.0160.000304%Not Available
Combined pulmonary fibrosis and emphysema22.01.02.0280.000082%Not Available
Device allergy10.01.03.054; 08.07.01.0140.000280%Not Available
Disease complication08.01.03.0870.000123%Not Available
Haemorrhagic cholecystitis24.07.01.094; 09.03.01.0080.000164%Not Available
Hyperaesthesia teeth07.09.06.0050.000280%Not Available
Illness08.01.03.0910.001069%Not Available
Implant site erythema23.03.06.024; 12.07.02.040; 08.02.02.0400.000082%Not Available
Implant site extravasation12.07.02.042; 08.02.02.0420.000164%Not Available
Implant site swelling08.02.02.063; 12.07.02.0630.000082%Not Available
Infusion site bruising24.07.06.030; 23.03.11.034; 12.07.05.022; 08.02.05.0220.000461%Not Available
Infusion site discharge12.07.05.025; 08.02.05.0250.003043%Not Available
Infusion site discolouration23.03.03.084; 12.07.05.026; 08.02.05.0260.000962%Not Available
Infusion site discomfort12.07.05.027; 08.02.05.0270.001003%Not Available
Infusion site erosion12.07.05.028; 08.02.05.028; 23.07.03.0270.000321%Not Available
Infusion site injury12.07.05.031; 08.02.05.0310.000280%Not Available
Infusion site mass12.07.05.032; 08.02.05.032--Not Available
Infusion site nodule23.07.04.042; 12.07.05.034; 08.02.05.0340.000642%Not Available
Infusion site scab23.03.03.085; 12.07.05.035; 08.02.05.0350.000419%Not Available
Infusion site scar08.02.05.036; 23.03.11.035; 12.07.05.0360.000543%Not Available
Infusion site streaking12.07.05.037; 08.02.05.0370.000280%Not Available
Infusion site vesicles23.03.01.036; 08.02.05.038; 12.07.05.0380.000502%Not Available
Injection site discharge12.07.03.057; 08.02.03.0570.001711%Not Available
Injection site erosion12.07.03.058; 08.02.03.058; 23.07.03.0280.000280%Not Available
Injection site scab08.02.03.069; 23.03.03.088; 12.07.03.0690.000181%Not Available
Lung transplant rejection22.01.01.029; 12.02.07.015; 10.02.03.0110.000082%Not Available
Malabsorption from injection site12.07.03.071; 08.02.03.0710.000222%Not Available
Sinus pain22.12.03.0230.000280%
Sleep deficit17.15.04.0100.000280%Not Available
The 14th Page    First    Pre   14 15    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene